Arrowhead Pharmaceuticals Corp (ARWR) Q4 Revs Beat
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $79.90 -2.56%
EPS Growth %: +4.8%
Financial Fact:
NET INCOME (LOSS): -19.42M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: +4.8%
Financial Fact:
NET INCOME (LOSS): -19.42M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q4 EPS of $0.11, $0.06 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $43.29 million versus the consensus estimate of $41.48 million.
Fiscal Year 2019 revenue was $168.796 million, EPS was $0.69.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
- SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
